Difference between revisions of "Team:AQA Unesp"

Line 12: Line 12:
 
}
 
}
 
function changeText2() {
 
function changeText2() {
−
document.getElementById("text").innerHTML="<img src='https://static.igem.org/mediawiki/2017/d/d7/T--AQA_Unesp--sensing.png' id='man_title2'>Aliquam mattis venenatis est, vel porttitor quam feugiat at. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Curabitur quis ex consectetur tortor dictum hendrerit at quis orci.";
+
document.getElementById("text").innerHTML="<img src='https://static.igem.org/mediawiki/2017/d/d7/T--AQA_Unesp--sensing.png' id='man_title2'>We don’t want to produce insulin the whole time  without any control! So, the bacteria needs to sense and control its production. We will build a control system based on the natural L. lactis system for catabolite repression along with regulation by a small RNA (sRNA).
 +
The CcpA protein is the protein responsible for control the gene expression in gram-positive bacteria, this protein is activated when glucose is present and then it binds to the DNA at the catabolite repression site (CRE) and represses the expression of downstream gene. We will put a coding sequence for a sRNA under the control of a promoter containing a CRE site, that targets the RBS site and the start codon of the mRNA coding the insulin gene, blocking its translation.  
 +
This way, when there is no glucose, the expression of our sRNA will be on and will block the production of insulin. Where there is glucose, the expression of our sRNA will be off and we will have the production of insulin. The produced insulin then is ready to be secreted and absorbed.";
 
}
 
}
 
function changeText3() {
 
function changeText3() {
−
document.getElementById("text").innerHTML="<img src='https://static.igem.org/mediawiki/2017/d/d1/T--AQA_Unesp--actuating.png' id='man_title3'>Curabitur sodales scelerisque metus efficitur fringilla. In id sollicitudin ante, ac volutpat nulla. Etiam at turpis dui. Praesent mi magna, ultricies quis fermentum vitae, malesuada sed augue.";
+
document.getElementById("text").innerHTML="<img src='https://static.igem.org/mediawiki/2017/d/d1/T--AQA_Unesp--actuating.png' id='man_title3'>We need our insulin to be secreted by our bacteria so the insulin gene will have an secretion signal sequence called usp45 which allows L. lactis to secrete proteins. The insulin that we will be using is a single-chain analog called SCI-57 that can be produced by bacteria and maintain its biological activity. Once the insulin is out, it needs to be absorbed by the intestinal epithelium, so our insulin will be associated with cell-penetrating peptides (CPPs) that allow the uptake of the insulin, which will reach the blood and then perform its biological function.";
 
}
 
}
 
function cleanText() {
 
function cleanText() {
−
document.getElementById("text").innerHTML="Lorem ipsum dolor sit amet, consectetur adipiscing elit. In sed pellentesque leo, at auctor neque. Maecenas rutrum justo vel tempor dictum. Duis lacus purus, tempor at turpis quis, hendrerit viverra lorem. Aliquam mattis venenatis est, vel porttitor quam feugiat at. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Curabitur quis ex consectetur tortor dictum hendrerit at quis orci. Vestibulum feugiat, odio nec gravida fermentum, urna felis rhoncus lorem, in viverra nibh ligula mollis ante. Suspendisse vel magna quis libero mattis dapibus sed dictum dolor. Curabitur sodales scelerisque metus efficitur fringilla. In id sollicitudin ante, ac volutpat nulla. Etiam at turpis dui. Praesent mi magna, ultricies quis fermentum vitae, malesuada sed augue.";
+
document.getElementById("text").innerHTML="In our first time ever participating in iGEM, our project is to develop a new treatment for diabetes mellitus type 1 (DM1). We want to engineer a Lactococcus lactis strain to live in the human gut and produce an insulin analog that can be absorbed by the intestinal epithelium. The number of DM1 patients and deaths due to DM1 is increasing every year and we want to make those people’s life better: no more several insulin injections in a single day!
 +
Our engineered L. lactis will produce a single-chain insulin analog associated with cell-penetrating peptides (CPPs) that facilitate the uptake of insulin by the intestinal epithelium. The expression of insulin will occur under a glucose control built using the catabolite repression system of gram-positive bacteria along with regulation by a small RNA.
 +
<b>Mouse over the image to learn more!</b>
 +
";
 
}
 
}
 
</script>
 
</script>

Revision as of 02:40, 30 June 2017



iGEM AQA_Unesp
.

Team: AQA_Unesp

Treating diabetes with probiotics


Lorem ipsum dolor sit amet, consectetur adipiscing elit. In sed pellentesque leo, at auctor neque. Maecenas rutrum justo vel tempor dictum. Duis lacus purus, tempor at turpis quis, hendrerit viverra lorem. Aliquam mattis venenatis est, vel porttitor quam feugiat at. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Curabitur quis ex consectetur tortor dictum hendrerit at quis orci. Vestibulum feugiat, odio nec gravida fermentum, urna felis rhoncus lorem, in viverra nibh ligula mollis ante. Suspendisse vel magna quis libero mattis dapibus sed dictum dolor. Curabitur sodales scelerisque metus efficitur fringilla. In id sollicitudin ante, ac volutpat nulla. Etiam at turpis dui. Praesent mi magna, ultricies quis fermentum vitae, malesuada sed augue.

Team: AQA_Unesp